Portnoy Law Firm Announces Class Action on Behalf of Beta Bionics, Inc. Investors

LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Beta Bionics, Inc., (“Beta Bionics” or the "Company") (NASDAQ: BBNX) investors of a class action on behalf of investors that bought securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/beta-bionics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Beta Bionics is a commercial-stage medical device company that engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.  Beta Bionics offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”).  In October 2025, Beta Bionics allegedly disclosed that it had received a Form 483 from the U.S. Food and Drug Administration (“FDA”) raising concerns about iLet.  According to the complaint, defendants stressed that the letter had nothing to do with the safety or efficacy of the device itself, and that the FDA had only taken issue with Beta Bionics’ interpretation of which customer complaints needed to be reported to the FDA, such that Beta Bionics would have to back-file some additional customer complaints that were very minor in nature and required no medical intervention.  The complaint further alleges that defendants assured investors that Beta Bionics was swiftly implementing the FDA’s required changes to its complaint reporting system, and accordingly that they did not “foresee any ongoing challenge with this at all.”

The Beta Bionics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the FDA had raised numerous serious issues with the iLet device itself, namely that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events; (ii) contrary to defendants’ assertions that the complaints back-filed with the FDA pursuant to the Form 483 were of no moment and entirely benign, they instead numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention; and (iii) the FDA was not satisfied with Beta Bionics’ response to the issue, as Beta Bionics had utterly failed to implement any meaningful corrective actions. 

On January 8, 2026, after markets closed, Beta Bionics allegedly reported an unexpected miss on new iLet patient starts.  According to the complaint, the announcement revealed that facts reported previously by the Capitol Forum in December – that Beta Bionics had received over 18,000 complaints out of less than 30,000 patients and failed to investigate, report to the FDA, or take corrective action – were credible and beginning to tell in Beta Bionics’ performance.  On this news, the price of Beta Bionics common stock dropped 37%, according to the complaint.

On January 30, 2026, Beta Bionics’ allegedly filed a Form 8-K that disclosed that the FDA had sent Beta Bionics a warning letter connected to its earlier Form 483.  The complaint alleges that Beta Bionics conceded that the FDA’s concerns were more serious than the minor difference in reporting-rule interpretation Beta Bionics had previously acknowledged.  On this news, the price of Beta Bionics common stock fell further, according to the complaint.

On February 24, 2026, the FDA allegedly released the warning letter to the public.  The complaint alleges that the warning letter contradicted Beta Bionics’ complacent framing of the FDA’s concerns – and the underlying issues with iLet – making clear that any malfunction that could be life threatening must be reported to the FDA.  The complaint further alleges the warning letter elaborated that any hypoglycemia requiring medical intervention was reportable because any such episode, even if resolved by giving a patient candy, raises the chances of future hypoglycemic episodes, likely more severe than the first and potentially leading to irreversible side effects, including death.  On this news, the price of Beta Bionics stock declined further, according to the complaint.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising